The new strategic partnership aims to add value to branded prescription medicines. Pharmanovia will look to apply Nanoform’s proprietary nanoparticle technologies and formulation know-how to leading established pharmaceutical brands.
The partnership starts with an iconic branded medicine where both parties see value in enhancing bioavailability for patient benefit. The value of the stage-gated agreement is according to Nanoform’s business model for non-GMP and cGMP work.
“This partnership is a great example of where the power of small can add value for iconic medicines to make them even more effective. Pharmanovia’s business model enables brand loyalty to continue from one generation to the next,” said Christian Jones, Chief Commercial Officer of Nanoform.